XML 25 R13.htm IDEA: XBRL DOCUMENT
v3.25.2

INVESTMENTS AND NOTE RECEIVABLE | 6 Months Ended
--- | ---
Jun. 30, 2025
Equity Method Investments and Joint Ventures [Abstract] |
INVESTMENTS AND NOTE RECEIVABLE | NOTE 5 - INVESTMENTS AND NOTE RECEIVABLE The Company holds various equity investments. The following table summarizes our investment balances:
(in thousands) | June 30, 2025 |  | December 31, 2024
Equity investments under the equity method of accounting | $ | 3,362 |  |  | $ | 5,051 |
Equity investments without readily determinable fair values | 21,712 |  |  | 20,696 |
Total equity investments | $ | 25,074 |  |  | $ | 25,747 |
During the three months ended June 30, 2025, the Company purchased additional shares of an equity method investment in Enhatch Inc. ("Enhatch") for $0.9 million. As of June 30, 2025, the Company owns approximately 79% of Enhatch's outstanding common stock and approximately 46% of Enhatch's outstanding voting stock. During the three months ended June 30, 2025, the Company entered into an agreement with GenesisTissue Inc. ("GenesisTissue") to obtain shares of common stock in exchange for the sale of certain assets. As of June 30, 2025, the Company owns approximately 8% of GenesisTissue's outstanding common stock. The Company has accounted for its investment in GenesisTissue on a cost basis, subject to assessment for impairment, as (1) the fair value of GenesisTissue's equity is not readily determinable and (2) the investment is not subject to the equity method of accounting due to the Company's lack of significant influence. The carrying value of the equity investment without a readily determinable fair value is $1.0 million as of June 30, 2025. The investment is reported in Other assets on our Condensed Consolidated Balance Sheets. Note Receivable - Related Party In February 2023, we became a shareholder in a joint venture, National Additive Manufacturing Innovation ("NAMI") Joint Venture, formed with the Saudi Arabian Industrial Investments Company ("Dussur") for purposes of expanding the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. During December 2024, the Company entered into a short-term, non-interest bearing loan agreement with NAMI whereby NAMI borrowed $2.0 million to finance its working capital and capital expenditures requirements. The loan matured on June 30, 2025 and the parties are in the process of extending the maturity date. It is being accounted for at cost, which approximates fair value as of June 30, 2025. The carrying value of the related party note receivable was $2.0 million as of June 30, 2025 and December 31, 2024. The note receivable is reported in Prepaid expenses and other current assets, on our Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024, respectively. Additionally, during the three and six months ended June 30, 2025 and 2024, the Company entered into related party transactions with certain of our equity investments, including purchases and sales, but the transactions and related balances payable or receivable were not significant for the three and six months ended June 30, 2025 and 2024 and as of June 30, 2025 and December 31, 2024. Other Asset In February 2025, the Company provided financing of $1.0 million to Hull Legacy Media Corporation, a production company co-owned by Charles W. Hull, our EVP, Chief Technology Officer of our Regenerative Medicine business and a related party of the Company. The financing is recorded in Other assets on our Condensed Consolidated Balance Sheets as of June 30, 2025. Variable Interest Entities ("VIEs") The Company concluded that three of its investments are VIEs. These investments are not consolidated because we concluded that the Company is not the primary beneficiary. As of June 30, 2025, our maximum exposure to losses associated with the VIEs is limited to the $20.2 million carrying value of our investments in the VIEs, $2.0 million of which is included in Prepaid expenses and other current assets, with the remaining in Other assets on our Condensed Consolidated Balance Sheets. We have no other investments in unconsolidated entities that have been determined to be a VIE.

X
- Definition Investments And Notes Receivable + References No definition available. + Details
Name: | ddd_InvestmentsAndNotesReceivableTextBlock
Namespace Prefix: | ddd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration